02 · Clinical Findings
GLP-1 is a signaling peptide before it is a drug label
A video primer on the gut-to-brain signal behind a much bigger medical and cultural story.
GLP-1 is a naturally occurring signaling peptide, while GLP-1 medicines are drugs designed to act on the same biological system.
That distinction helps explain why appetite is part of the conversation, but it does not turn a broad mechanism into a prediction about how a medicine will affect one person.
Clinical trials and regulatory information, rather than a short explanatory video, are the evidence needed to judge a specific medicine’s benefits, risks or approved uses.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsA late-stage retatrutide result sets a benchmark, not a treatment answerThe Guardian · May 21, 2026 · scroll to read